| Literature DB >> 33907667 |
Valentina Rovelli1, Juri Zuvadelli1, Vittoria Ercoli1, Chiara Montanari1, Sabrina Paci1, Alice Re Dionigi1, Andrea Scopari1, Elisabetta Salvatici1, Graziella Cefalo1, Giuseppe Banderali1.
Abstract
BACKGROUND: COVID19 pandemic urged the need to take severe measures for reducing the epidemic spread. Lockdowns were imposed throughout countries and even Inborn errors of metabolism (IEMs) affected patients had to face it and adapt, with management strategies changes coming along. Phenylketonuria (PKU) is an inborn error of phenylalanine (Phe) metabolism causing, when not treated, blood Phe increases and consequent central nervous system (CNS) damage. Dietary intervention is the main recognized treatment and must be maintained long-life, however adherence is often suboptimal in adulthood. Aim of this study was to evaluate whether and how the pandemic had impacted PKUs metabolic control and what factors may have played a role as potential modifiers.Entities:
Keywords: Adherence; CNS, Central Nervous System; COVID-19; DBS, Dried Blood Spot; Diet; IEM, Inborn errors of metabolism; LD, Lockdown; Lockdown; MAM-2019, March–April-May 2019; MAM-2020, March–April-May 2020.; Metabolic control; PAH, phenylalanine hydroxylase; PKU; PKU, Phenylketonuria; Phe, phenylalanine; Tyrosine, (Tyr)
Year: 2021 PMID: 33907667 PMCID: PMC8063433 DOI: 10.1016/j.ymgmr.2021.100759
Source DB: PubMed Journal: Mol Genet Metab Rep ISSN: 2214-4269
PKU sample demographic characteristics.
| Demographics ( | ||
|---|---|---|
| GROUP A ( | GROUP B ( | |
| Age (y) | ||
| Mean (SD) | 8.4 (±2.0) | 26.8 (± 11.7) |
| Median (min-max) | 9.1 (4–11) | 24.0 (12–65) |
| Gender ( | ||
| M/F | 31/20 | 70/71 |
Fig. 1Percentages of patients changing monitoring frequencies among two analyzed time periods (MAM 2019 vs. MAM 2020) (a), also divided per age (b).
Metabolic control expressed by mean of Phe levels assessed with DBS among two analyzed time periods (MAM 2020 vs MAM 2019).
| Blood Phe values (umol/l) | |||
|---|---|---|---|
| MAM 2019 | MAM 2020 | ||
| GROUP A | |||
| Mean (SD) | 315.4 (114) | 309.2 (134) | 0.717 |
| Median (min-max) | 311.5 (85–586) | 287.8 (86–645) | |
| GROUP B | |||
| Mean (SD) | 556.4 (301) | 454 (252) | 0.000 |
| Median (min-max) | 478 (113–1612) | 409 (35–1525) | |
Significant values were considered for p < 0.05.
Fig. 2Changes in blood Phe values according to age, comparing MAM 2019 vs. MAM 2020 time-period. ⁎ = statistically significant (p values <0.05); ⁎⁎ = statistically significant (p values <0.01).
“Non-compliant” patients were also reduced (lowering from 11% to 3%) with also a finding of −14% of patients with mean Phe levels >600 umol/l and a − 8% of patients with 100% DBS above same level (results shown in Fig. 3).
Fig. 3Variations between percentages of PKU non-compliant patients during MAM 2019 vs MAM 2020.
No significant differences could be observed on a gender basis.